TY - JOUR
T1 - A pilot study of paternal drug exposure
T2 - The Motherisk experience
AU - Lee, Candace Y.W.
AU - Jin, Cheng
AU - Mata, Andrea M.
AU - Tanaka, Toshihiro
AU - Einarson, Adrienne
AU - Koren, Gideon
N1 - Funding Information:
Supported by the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation (GK); a fellowship from the Research Training Centre of the Hospital for Sick Children (CL); Nobel Pharma Scholarship, TFB Scholarship, Scholarship for Researchers through the Japanese Society of Clinical Pharmacology and Therapeutics, and The Research and Training Competition (RESTRACOMP) through the Hospital for Sick Children Research Institute (TT).
PY - 2010/6
Y1 - 2010/6
N2 - Background: There is a dearth of information on paternal drug exposure at the time of conception. The Motherisk Program, established in 1985, is a teratology information and clinical consultation service on drug safety during pregnancy and lactation, as well as paternal exposure (PEx). Here, we reviewed for the first time our experience with PEx. Methods: This was an observational retrospective cohort study using a prospectively collected database. Telephone counselling records from January 2002 to December 2007, inclusive, were screened to identify cases concerning PEx. Results: Of a total of 188,188 counselling requests over these 6 years, 301 (0.16%) pertained to PEx. Counselling was most frequently sought on methotrexate, finasteride, prednisone and azathioprine. For many drugs, limited or no information was available on PEx. Conclusions: Paternal exposure represents a small fraction of counselling requests to Motherisk. Our findings suggest that there is an ongoing need for information on paternal drug exposure.
AB - Background: There is a dearth of information on paternal drug exposure at the time of conception. The Motherisk Program, established in 1985, is a teratology information and clinical consultation service on drug safety during pregnancy and lactation, as well as paternal exposure (PEx). Here, we reviewed for the first time our experience with PEx. Methods: This was an observational retrospective cohort study using a prospectively collected database. Telephone counselling records from January 2002 to December 2007, inclusive, were screened to identify cases concerning PEx. Results: Of a total of 188,188 counselling requests over these 6 years, 301 (0.16%) pertained to PEx. Counselling was most frequently sought on methotrexate, finasteride, prednisone and azathioprine. For many drugs, limited or no information was available on PEx. Conclusions: Paternal exposure represents a small fraction of counselling requests to Motherisk. Our findings suggest that there is an ongoing need for information on paternal drug exposure.
KW - Canada
KW - Motherisk
KW - Paternal exposure
KW - Teratology information service
UR - https://www.scopus.com/pages/publications/77951533032
U2 - 10.1016/j.reprotox.2010.01.008
DO - 10.1016/j.reprotox.2010.01.008
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 20096774
AN - SCOPUS:77951533032
SN - 0890-6238
VL - 29
SP - 353
EP - 360
JO - Reproductive Toxicology
JF - Reproductive Toxicology
IS - 3
ER -